We were unable to process your request. Please try again later. If you continue to have this issue please contact [email protected]. The PATHFNDR-2 trial enrolled adults with acromegaly who ...

The regulatory greenlight was backed by two Phase III trials that showed normalized growth hormone levels in patients with ...

The Food and Drug Administration (FDA) has approved Palsonify ™ (paltusotine) for the treatment of adults with acromegaly who had an inadequate response to surgery and/or for whom surgery is not an ...

The U.S. Food and Drug Administration approved Crinetics Pharmaceuticals' drug to treat a rare hormonal disorder on Thursday, making it the first once-daily oral pill available for patients in the ...

Findings showed 56% of patients who received paltusotine achieved an IGF-1 level equal to or less than 1 times the ULN compared with 5% of those who received placebo. Treatment with paltusotine ...

We present a review of the epidemiological evidence for relations of prostate cancer risk to circulating total and bioavailable androgens, to alterations in the metabolism of insulin-like growth ...

We were unable to process your request. Please try again later. If you continue to have this issue please contact [email protected]. Back to Healio More than 80% of adults with acromegaly ...